Commission chairman describes an upcoming retirement while director disputes leaving
by SPEAKIN’ OUT NEWS
Alabama’s medical cannabis program faces a new leadership question after its commission chairman and executive director offered conflicting accounts of whether the agency’s top administrator intends to leave later this month.
Alabama Political Reporter reported October 19 that commission Chairman Sam Blakemore said executive director John McMillan would retire October 29. McMillan disputed that account in comments to the outlet, saying he did not plan to step down.
“Not me,” McMillan told APR when asked specifically about retiring or resigning later this month.
The conflicting statements leave the departure unconfirmed. Blakemore’s account should not be treated as an announced resignation accepted by McMillan, and McMillan’s denial does not resolve why the chairman described a transition.
The dispute comes while the state continues navigating the process for integrated medical cannabis licenses. APR reported that applicants had presented their cases during an administrative hearing and were awaiting a ruling.
The commission’s published business guidance shows why those licenses carry substantial commercial weight. An integrated license covers cultivation, processing, and dispensing, as well as specified transportation and transfers. The commission lists a limit of five licenses, with each licensee allowed up to five dispensing sites.
Its guidance lists a $50,000 annual integrated-facility license fee. That fee is a regulatory charge, not a measure of the full investment required to operate a business.
For applicants, employees, and prospective patients, leadership questions and licensing decisions are separate issues. A personnel change, if confirmed, would not by itself establish that an applicant has received authorization or that products are available.
The immediate unanswered questions are whether McMillan will remain, how any replacement would be selected, and what happens next in licensing. The sources reviewed do not establish a final leadership transition or a statewide sales opening date.